Literature DB >> 36097444

Peptide-Based HDL as an Effective Delivery System for Lipophilic Drugs to Restrain Atherosclerosis Development.

Junwei Gao1, Ziyun Li1, Jing Li2, Ping Song3, Jinsheng Yang1, Wei Xiao4, Ning Li1, Ruodan Xu1.   

Abstract

Purpose: Peptide-based high-density lipoprotein (pHDL) structurally and functionally resembles the natural HDL as anti-atherosclerosis (AS) therapies. Since pHDL contains a large hydrophobic core, this study aims to evaluate the potentials of pHDL as a hydrophobic drug carrier and the efficiency of drug-loaded pHDL in the control of AS.
Methods: The pHDL encapsulation of hydrophobic components from natural plants, including curcumin (Cur) and tanshinone IIA (TanIIA), was achieved using one-step microfluidics. Then, morphological features and loading efficiencies of pHDL-Cur and pHDL-TanIIA were determined by TEM and high-performance liquid chromatography (HPLC), respectively. Taking the fluorescence advantage of Cur, localizations of loaded Cur in pHDL were investigated by fluorescence quenchers, and recruitments of Cur to AS plaques were assessed with ex vivo imaging. Based on anti-inflammatory properties of TanIIA, pHDL-TanIIA was accordingly developed to evaluate the anti-AS effects through examinations of plasma lipid parameters and pathological alterations of plaque-associated regions.
Results: Both lipophilic Cur and TanIIA can be efficiently loaded into pHDL carriers. The resultant pHDL-Cur and pHDL-TanIIA inherit the homogeneous nano-disk structure of pHDL. By using pHDL-Cur, the encapsulated hydrophobics are tracked in the core of pHDL, and incorporations of Cur with pHDL vehicles greatly improve the bioavailability and association of Cur with AS plaques. Moreover, when loaded with TanIIA, which has established its role in anti-AS as an anti-inflammatory candidate, synergistic effects in reducing AS lesions and improving pathological alterations of main organs related to AS were achieved.
Conclusion: The pHDL system could potentially be applied for both imaging and therapy in animal models of AS. Benefits of pHDL-based drug delivery will potentially extend the application scenarios of bioactive chemicals from natural plants which are underutilized due to features like low bioavailability and facilitate the clinical translation of synthetic HDL therapies in HDL-associated disorders, including but not limited to AS.
© 2022 Gao et al.

Entities:  

Keywords:  HDL; antiatherogenic therapy; atherosclerosis; drug delivery; natural plants; peptide-based HDL

Mesh:

Substances:

Year:  2022        PMID: 36097444      PMCID: PMC9464027          DOI: 10.2147/IJN.S374736

Source DB:  PubMed          Journal:  Int J Nanomedicine        ISSN: 1176-9114


  31 in total

Review 1.  High-Density Lipoproteins: Nature's Multifunctional Nanoparticles.

Authors:  Rui Kuai; Dan Li; Y Eugene Chen; James J Moon; Anna Schwendeman
Journal:  ACS Nano       Date:  2016-02-25       Impact factor: 15.881

Review 2.  HDL-targeted therapies: progress, failures and future.

Authors:  Bronwyn A Kingwell; M John Chapman; Anatol Kontush; Norman E Miller
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

3.  Curcumin Protects against Atherosclerosis in Apolipoprotein E-Knockout Mice by Inhibiting Toll-like Receptor 4 Expression.

Authors:  Shanshan Zhang; Jun Zou; Peiyang Li; Xiumei Zheng; Dan Feng
Journal:  J Agric Food Chem       Date:  2018-01-02       Impact factor: 5.279

Review 4.  Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage.

Authors:  Renu Virmani; Frank D Kolodgie; Allen P Burke; Aloke V Finn; Herman K Gold; Thomas N Tulenko; Steven P Wrenn; Jagat Narula
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-07-21       Impact factor: 8.311

5.  HDL-mimetic PLGA nanoparticle to target atherosclerosis plaque macrophages.

Authors:  Brenda L Sanchez-Gaytan; Francois Fay; Mark E Lobatto; Jun Tang; Mireille Ouimet; YongTae Kim; Susanne E M van der Staay; Sarian M van Rijs; Bram Priem; Liangfang Zhang; Edward A Fisher; Kathryn J Moore; Robert Langer; Zahi A Fayad; Willem J M Mulder
Journal:  Bioconjug Chem       Date:  2015-02-13       Impact factor: 4.774

6.  Nascent high density lipoproteins formed by ABCA1 resemble lipid rafts and are structurally organized by three apoA-I monomers.

Authors:  Mary G Sorci-Thomas; John S Owen; Brian Fulp; Shaila Bhat; Xuewei Zhu; John S Parks; Dharika Shah; W Gray Jerome; Mark Gerelus; Manal Zabalawi; Michael J Thomas
Journal:  J Lipid Res       Date:  2012-06-29       Impact factor: 5.922

Review 7.  Recent advances in nanomaterials for therapy and diagnosis for atherosclerosis.

Authors:  Jun Chen; Xixi Zhang; Reid Millican; Jennifer Sherwood; Sean Martin; Hanjoong Jo; Young-Sup Yoon; Brigitta C Brott; Ho-Wook Jun
Journal:  Adv Drug Deliv Rev       Date:  2021-01-09       Impact factor: 15.470

Review 8.  Nanomaterials for cancer therapy: current progress and perspectives.

Authors:  Zhe Cheng; Maoyu Li; Raja Dey; Yongheng Chen
Journal:  J Hematol Oncol       Date:  2021-05-31       Impact factor: 17.388

Review 9.  Pharmacological Activity and Mechanism of Tanshinone IIA in Related Diseases.

Authors:  Rui Guo; Lan Li; Jing Su; Sheng Li; Sophia Esi Duncan; Zhihao Liu; Guanwei Fan
Journal:  Drug Des Devel Ther       Date:  2020-11-05       Impact factor: 4.162

10.  Zein Nanoparticles Improve the Oral Bioavailability of Curcumin in Wistar Rats.

Authors:  Ana Brotons-Canto; Carlos J González-Navarro; Ana Gloria Gil; Eduardo Asin-Prieto; María José Saiz; Josep Manuel Llabrés
Journal:  Pharmaceutics       Date:  2021-03-09       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.